SURVIVING THANKS TO RESEARCH
The McPeak-Sirois Group and the Quebec Breast Cancer Foundation join forces to launch the Accès-recherche program. This program aims at increasing access to clinical research in breast cancer for patients in all regions in Québec. Discover this major breakthrough in clinical research which is at the heart of both organizations’ mission.
BEATING THE STATISTICS
Discover the story of Susan McPeak, co-founder of the McPeak-Sirois Group, who was diagnosed with metastatic breast cancer and beat statistics by participating in a clinical trial.
RESEARCH THAT CARES
Clinical research is one of the best means to fight breast cancer.
Dr. André Robidoux, Founding President of the Scientific Committee of the McPeak-Sirois Group and Surgical Oncologist at the Centre hospitalier de l’Université de Montréal, explains why.
UNITED FOR RESEARCH
The McPeak-Sirois Group and the Quebec Breast Cancer Foundation join forces to launch the Accès-recherche program. Discover this unique collaboration between two organizations committed to improving access to clinical research.
The Accès-recherche program aims to increase the number of hospital centres in Quebec participating in clinical trials in breast cancer to increase access to state-of-the-art treatments for more women in all regions in Quebec.
THE IMPLICATION AT THE HEART OF ACTION
Discover the origin of Susan McPeak and Charles Sirois’ unique commitment to clinical research in breast cancer in Quebec: giving patients the chance to access the best available care. (French only)
THE STRENGTH OF COLLABORATIONS
The strength of collaborations, embodied by the work of Susan McPeak, has inspired the 2019 Audacious benefit evening organized by IRIC, an opportunity to recognize the involvement of our Co-Founder. (French only)
SUSAN MCPEAK'S INTERVIEW AT AUDACE 2019
It is with great pride that Susan McPeak, co-founder of the McPeak-Sirois Group, was recognized for her contribution to the fight against Breast Cancer on May 29th during the 6th edition of the Audacious benefit event organized by Institute for Research in Immunology and Cancer (IRIC)
of the Université de Montréal. (French only)
DR. HASSAN'S INTERVIEW AT SABCS 2020
Dr. Saima Hassan, Surgical-oncologist at the CHUM presents the results
of an investigator-driven study on the impact of 21-Gene Breast Recurrence
Score® upon physician treatment decision in Quebec.
DR. ASSELAH'S INTERVIEW WITH ONCOXCHANGE
In an interview with OncoXchange, Dr. Jamil Asselah, Medical Oncologist
at the MUHC and Vice-President of our Executive Scientifc Committe,
discusses the unexpected medium and long term impact of COVID-19
on the treatment of breast cancer in Quebec.
DR. BOILEAU'S INTERVIEW WITH ONCOXCHANGE
In an interview with OncoXchange, Dr. Jean-François Boileau,
Surgical Oncologist at the Jewish General Hospital of the CIUSSS
West-Central Montreal, gives a Quebec clinical perspective on the
randomized clinical trial SWOG S1007 (RxPonder) and its impact on patients.
DR. YOUNAN'S INTERVIEW WITH ONCOXCHANGE
In an interview with OncoXchange, Dr. Rami Younan, Surgical Oncologist
at the CHUM gives a Quebec clinical perspective on the
randomized clinical trial MonarchE (NSABP-B58) and its impact on patients.
DR. ASSELAH'S INTERVIEW AS NEW PRESIDENT OF OUR EXECUTIVE SCIENTIFIC COMMITTEE
Discover the interview of Dr. Jamil Asselah, Medical Oncologist at the McGill University Health Centre, about his appointment as President of the Group’s Executive Scientific Committee.